Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 1.08 -0.02 (-1.82%) Market Cap: 276.01 Mil Enterprise Value: 162.44 Mil PE Ratio: 0 PB Ratio: 10.80 GF Score: 70/100

Q3 2021 Adaptimmune Therapeutics PLC Earnings Call Transcript

Nov 04, 2021 / 12:00PM GMT
Release Date Price: $5.25 (-4.02%)
Operator

Good day, and thank you for standing by. Welcome to the Q3 2021 Adaptimmune Earnings Conference Call. (Operator Instructions) After the speaker presentation, there will be a question-and-answer session. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Juli Miller. Please go ahead.

Juli P. Miller
Adaptimmune Therapeutics plc - Senior Director of IR

Good morning, and welcome to Adaptimmune's conference call to discuss our third quarter 2021 financial results and business updates.

Please review our forward-looking statements from this morning's press release as we anticipate making projections during this call, and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC.

Adrian Rawcliffe, our Chief Executive Officer, is with me for the prepared portion of this call. Other members of our management team will be available for Q&A.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot